As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending

Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.

Dominoes falling on gray background
Signs have emerged that the pandemic slowed the pace of new drug applications. • Source: Shutterstock

A substantial drop in prescription drug user fee revenue last year, suspected to have been caused by delayed application submissions, forced the US Food and Drug Administration to scale back user-fee-related capacity planning.

The agency suggested in a 25 February notice to government contractors that the “unexpected and large drop in collections”...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet